# ThyraMIR v2

Source: https://onco.cc/drugs/thyramir-v2/  
OnCo record `thyramir-v2` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ThyraMIR v2 is a test from Interpace Biosciences that measures small RNA molecules in a thyroid nodule sample to help judge how likely it is to be cancer.

## Summary

ThyraMIR v2 is Interpace Biosciences' microRNA-based endocrine cancer test, used with ThyGeNEXT on indeterminate thyroid nodules. Interpace reports that Labcorp was the largest customer for the pair in 2025 and the first half of 2026.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-04
- Tags: pipeline
- Modality: Thyroid nodule microRNA expression test
- Mechanism: An algorithmic, pairwise microRNA expression analysis that refines the malignancy risk of an indeterminate thyroid nodule when combined with the ThyGeNEXT mutation panel, as described by Interpace Biosciences.

## Sources

- SEC: Interpace Biosciences Form S-1/A, October 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226049456/forms-1a.htm

## Connected records

- technologies: [Thyroid nodule FNA, Bethesda cytology & molecular classifiers](https://onco.cc/technologies/thyroid-fna-molecular/)
- drugs: [ThyGeNEXT](https://onco.cc/drugs/thygenext/)
- companies: [Interpace Biosciences](https://onco.cc/companies/interpace-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/thyramir-v2.json